Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data

Boggs, Jennifer
May 2010
BioWorld International;5/5/2010, Vol. 15 Issue 18, p5
The article deals with the preliminary Phase I data released by Pluristem Therapeutics Inc. for its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia in May 2010. Information on the Phase I trial results is presented. It discloses the company's negotiations for a Phase II program slated in the first quarter of 2011.


Related Articles

  • PLURISTEM GETS INTERIM TOP-LINE RESULTS FROM PLX-PAD TRIALS.  // Worldwide Biotech;Jun2010, Vol. 22 Issue 6, p3 

    The article reports on the interim top-line results from the Phase I clinical trials of Pluristem Therapeutics Inc. in Haifa, Israel, in June 2010, which utilize the placenta-derived cell therapy product PLX-PAD for treating critical limb ischemia (CLI). The interim data showed that PLX-PAD is...

  • PLURISTEM GETS DSMB APPROVAL FOR PLX-PAD FINAL DOSE LEVEL.  // Biotech Business;Apr2010, Vol. 23 Issue 4, p6 

    The article announces the approval received by Pluristem Therapeutics Inc. of Haifa, Israel from the Safety Monitoring Board to advance to the highest and final dose level with its placenta-derived cell therapy (PLX-PAD) trial in Europe for the treatment of critical limb ischemia (CLI). Dr. Hans...

  • Pluristem's Placenta-Derived Cell Therapy Yields Strong Early Data. Boggs, Jennifer // BioWorld Today;4/28/2010, Vol. 21 Issue 81, p1 

    This article reports on the plan of Pluristem Therapeutics Inc. to conduct Phase II testing with its placenta-derived cell therapy treatment PLX-PAD in critical limb ischemia. The Israeli company announced the plan after reporting positive results from two Phase I trials of the treatment,...

  • Regenerative Therapy in Peripheral Artery Disease. Germani, Antonia; Di Campli, Cristiana; Pompilio, Giulio; Biglioli, Paolo; Capogrossi, Maurizio C. // Cardiovascular Therapeutics;Dec2009, Vol. 27 Issue 4, p289 

    Patients with peripheral artery disease (PAD) and critical limb ischemia are the main candidates for limb amputations and have a poor life expectancy. Frequently, these patients are not eligible for either surgical or percutaneous interventions aimed at mechanical revascularization. Therefore,...

  • Financings Roundup.  // BioWorld Today;9/24/2008, Vol. 19 Issue 186, p5 

    The article reports that Pluristem Therapeutics Inc. of New York City has raised additional fundings of $1 million in September 2008. These new fundings will be used to support the development of their preclinical allogenic, placenta-derived cell therapy products. As reported, Pluristem sold...

  • Placenta-Derived Cell Therapy Yields Strong Data.  // Bioworld Week;5/3/2010, Vol. 18 Issue 18, p3 

    The article discusses the phase II testing of placenta-derived cell therapy treatment PLX-PAD in vital limb ischemia as supported by Pluristem Therapeutics Inc.

  • PLURISTEM COMPLETES DOSING FOR FIRST PATIENTS IN CLI TRIAL.  // Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p6 

    The article reports on the completion by Pluristem Therapeutics Inc. of dosing of the first of three dosage groups of patients in Europe as part of its Phase I dose-escalating clinical trial of its placenta-derived cell therapy product PLX-PAD, for the treatment of critical limb ischemia (CLI)....

  • Cell Therapy Treatment for Critical Limb Ischemia. Prather, William R. // Drug Discovery & Development;Nov/Dec2009, Vol. 12 Issue 10, p40 

    The article discusses the treatment of the peripheral artery disease (PAD) critical limb ischemia (CLI) through cell therapy. It is stated that clinical trials are conducted by Pluristem Therapeutics Inc. in the U.S. and Europe to identify the effectiveness of adherent stromal cell (ASC) in...

  • Pluristem's PLX-PAD Plans Boosted by $36M Offering. Boggs, Jennifer // BioWorld Today;1/28/2011, Vol. 22 Issue 19, p1 

    The article offers information on the public offering held by Pluristem Theraprutics Inc. to secure funding for its plans for a Phase II/III trial of placenta-derived cell therapy PLX-PAD for critical limb ischemia (CLI). The offering involved 11 million shares sold at 3.25 U.S. dollars each,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics